Skip to main content
SpringerLink
Log in

NRD 101

  • New Drug Profile
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

Summary

  • ▲ NRD 101 is a high molecular weight hyaluronan derivative used in the treatment of osteoarthritis.

  • ▲ The benefits of intra-articular hyaluronan are believed to be primarily a consequence of their lubricating and shock-absorbing properties, but it also has anti-inflammatory and analgesic effects.

  • ▲ NRD 101 inhibited leucocyte chemotaxis and phagocytosis in guinea-pig polymorphonuclear leucocytes.

  • ▲ NRD 101 was also associated with normalisation of joint loading in meniscectomised sheep but did not have a chondrocyte-protective effect.

  • ▲ In several clinical trials, intra-articular NRD 101 was associated with improvements in symptoms of osteoarthritis compared with baseline on physician or patient rating scales and produced a significantly higher response rate than a lower molecular weight hyaluronan (Artz®).

  • ▲ NRD 101 is well tolerated; approximately 2 to 3% of patients in clinical trials experienced adverse events, most commonly transient, mild to moderate joint pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tamoto K, Nochi H, Tokumitsu Y. High molecular weight hyaluronic acids inhibit interleukin-1-induced prostaglandin E2 generation and prostaglandin E2-elicited cyclic AMP accumulation in human rheumatoid arthritic synovial cells. Jpn J Rheumatol 1994; 5(3): 227–36

    Google Scholar 

  2. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheumatol 1994 Jan–Feb; 12: 75–82

    PubMed  CAS  Google Scholar 

  3. Strachan RK, Smith P, Gardner DL. Hyaluronate in rheumatology and orthopaedics: is there a role? Ann Rheum Dis 1990 Nov; 49: 949–52

    Article  PubMed  CAS  Google Scholar 

  4. Pelletier J-P, Martel-Pelletier J. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. J Rheumatol 1993 Aug; 20Suppl. 39: 19–24

    Google Scholar 

  5. Peyron JG. Intraarticular hyaluronan injections in the treatment of osteoarthritis: state-of-the-art review. J Rheumatol 1993 Aug; 20Suppl. 39: 10–5

    Google Scholar 

  6. Tamoto K, Tada M, Shimada S, et al. Effects of high-molecular-weight hyaluronates on the functions of guinea pig polymorphonuclear leukocytes. Semin Arthritis Rheum 1993 Jun; 22(6): 4–8

    Article  PubMed  CAS  Google Scholar 

  7. Ghosh P, Read R, Armstrong S, et al. The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Semin Arthritis Rheum 1993 Jun; 22Suppl. 1: 18–30

    Article  PubMed  CAS  Google Scholar 

  8. Ghosh P, Read R, Numata Y, et al. The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. II. Cartilage composition and proteoglycan metabolism. Semin Arthritis Rheum 1993 Jun; 22Suppl. 1: 31–42

    Article  PubMed  CAS  Google Scholar 

  9. Iwata H, Itoh H, Onishi A. The phase I study of high molecular weight sodium hyaluronate (NRD101), a new anti-arthritis agent [in Japanese]. Yakuri to Chiryo 1994 Jun; 22(6): 2755–70

    Google Scholar 

  10. Fraser JRF, Kimpton WG, Pierscionek BK, et al. The kinetics of hyaluronan in normal and acutely inflamed synovial joints: observations with experimental arthritis in sheep. Semin Arthritis Rheum 1993 Jun; 22(6) Suppl 1: 9–17

    Article  PubMed  CAS  Google Scholar 

  11. Yamada N, Uzuki M, Ohnuma E, et al. Comparative study on synovial tissues of rheumatoid arthritis between pre and post treatment of hyaluronan with high molecular weight by the aid of immunohistochemistry [in Japanese]. Ensho 1994 Jul; 14(4): 303–11

    Article  Google Scholar 

  12. Yamamoto M, Takagishi K, Tsukamoto Y, et al. Clinical evaluation of high molecular sodium hyaluronate (NRD 101) on osteoarthritis of the knee [in Japanese]. Yakuri to Chiryo 1993 Mar; 21(3): 891–907

    Google Scholar 

  13. Yamamoto M, Kanbara S, Tsukamoto Y, et al. Dose-range finding study of high molecular weight sodium hyaluronate (NRD101) on osteoarthritis of the knee: a multi-center, late phase II clinical study [in Japanese]. Yakuri to Chiryo 1994 Jun; 22(3): 2771–94

    Google Scholar 

  14. Kurokawa T, Oda H, Mikami Y, et al. Clinical evaluation of high molecular weight sodium hyaluronate (NRD101) on osteoarthritis of the knee: phase III long-term clinical study [in Japanese]. Yakuri to Chiryo 1994 Sep; 22(9): 4007–28

    Google Scholar 

  15. Yamamoto M, Sugawara Y, Tsukamoto Y, et al. Clinical evaluation of high molecular weight sodium hyaluronate (NRD 101) on osteoarthritis of the knee: a phase III comparative clinical study with ARTZ® as a control drug [in Japanese]. Yakuri to Chiryo 1994 Sep; 22(9): 4059–87

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Bret Fulton & Harriet M. Bryson

Authors
  1. Bret Fulton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harriet M. Bryson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fulton, B., Bryson, H.M. NRD 101. Clin. Immunother. 6, 163–168 (1996). https://doi.org/10.1007/BF03259513

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259513

Keywords

Search

Navigation